A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors



Status:Not yet recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:16 - 23
Updated:12/9/2018
Start Date:December 30, 2018
End Date:June 30, 2022
Contact:Giselle K. Perez, PhD
Email:Gperez@mgh.harvard.edu
Phone:617-724-4000

Use our guide to learn which trials are right for you!

A Stress Management and Resiliency Program for Adolescent and Young Adult Cancer Survivors

This research study aims to explore the feasibility and acceptability of an adapted
resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to
reduce stress and promote stress-management among adolescents and young adults who have
completed treatment for cancer.

The Relaxation Response Resiliency Program, or 3RP, was developed by researchers at the MGH
Benson-Henry Institute for Mind Body Medicine. The 3RP is a group program that—through a
variety of mind-body approaches, such as imagery, relaxation, and yoga—seeks to buffer stress
and promote psychological resiliency and physical well-being.

The 3RP has not yet been carried out with adolescent or young adult individuals who have
recently completed treatment for cancer. As such, the investigators have adapted the original
3RP to target the specific needs of adolescent and young adult patients who are transitioning
off active treatment. The investigators are conducting this study to see if the adapted
program, the 3RP-AYA, is effective at reducing stress and stress-related symptoms for people
of at least age 16 who have completed treatment for cancer within the past five years.

Inclusion Criteria:

- Diagnosed with any cancer between ages 15 and 23

- Completed cancer treatment within the past 5 years

- At least 16 years of age at time of enrollment

Exclusion Criteria:

- Unwilling or unable to participate in the study

- Unable to speak or read English

- Is medically or otherwise unable to participate (as determined by a physician or study
PI)

- Unwilling or unable to participate in study sessions delivered via the Partners
Telehealth videoconferencing software

- Participation in a focus group during Phase 1 (DF/HCC 17-315)
We found this trial at
1
site
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Giselle K. Perez, PhD
Phone: 617-724-4000
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials